54
| 1 | 2012
Klinisk Biokemi i Norden
(
Fortsat fra side 54)
Referenser
1.
Lee MM, Donahoe PK. Mullerian inhibiting
substance: a gonadal hormone with multiple
functions. Endocr Rev 1993;14:152-64.
2.
Josso N, Picard JY, Rey R, et al. Testicular anti-
Mullerian hormone: history, genetics, regula-
tion and clinical applications. Pediatr Endocri-
nol Rev 2006;3:347-58.
3.
Visser JA, de Jong FH, Laven JS, et al. Anti-
Mullerian hormone: a new marker for ovarian
function. Reproduction 2006;131:1-9.
4.
Streuli I, Fraisse T, Chapron C, et al. Clinical
uses of anti-Mullerian hormone assays: pitfalls
and promises. Fertil Steril 2009;91:226-30.
5.
van Rooij IA, Broekmans FJ, Scheffer GJ, et
al. Serum antimullerian hormone levels best
reflect the reproductive decline with age in nor-
mal women with proven fertility: a longitudinal
study. Fertil Steril 2005;83:979-87.
6.
Silberstein T, MacLaughlin DT, Shai I, et al.
Mullerian inhibiting substance levels at the
time of HCG administration in IVF cycles pre-
dict both ovarian reserve and embryo morpho-
logy. Hum Reprod 2006;21:159-63.
7.
Lie Fong S, Laven JS, Hakvoort-Cammel FG, et
al. Assessment of ovarian reserve in adult child-
hood cancer survivors using anti-Mullerian
hormone. Hum Reprod 2009;24:982-90.
8.
Broekmans FJ, Visser JA, Laven JS, et al. Anti-
Mullerian hormone and ovarian dysfunction.
Trends Endocrinol Metab 2008;19:340-7.
9.
Pigny P, Merlen E, Robert Y, et al. Elevated
serum level of anti-mullerian hormone in
patients with polycystic ovary syndrome: rela-
tionship to the ovarian follicle excess and to
the follicular arrest. J Clin Endocrinol Metab
2003;88:5957-62.
10.
Piltonen T, Morin-Papunen L, Koivunen R,
et al. Serum anti-Mullerian hormone levels
remain high until late reproductive age and
decrease during metformin therapy in women
with polycystic ovary syndrome. Hum Reprod
2005;20:1820-6.
11.
Muttukrishna S, Suharjono H, McGarrigle
H, et al. Inhibin B and anti-Mullerian hor-
mone: markers of ovarian response in IVF/ICSI
patients? BJOG 2004;111:1248-53.
12.
Nakhuda GS, Chu MC, Wang JG, et al. Elevated
serummullerian-inhibiting substance may be a
marker for ovarian hyperstimulation syndrome
in normal women undergoing in vitro fertiliza-
tion. Fertil Steril 2006;85:1541-3.
13.
Isikoglu M, Ozgur K, Oehninger S, et al. Serum
anti-Mullerian hormone levels do not predict
the efficiency of testicular sperm retrieval in
men with non-obstructive azoospermia. Gyne-
col Endocrinol 2006;22:256-60.
14.
Lee MM, Misra M, Donahoe PK, et al. MIS/
AMH in the assessment of cryptorchidism
and intersex conditions. Mol Cell Endocrinol
2003;211:91-8.
15.
Schumer ST, Cannistra SA. Granulosa cell tumor
of the ovary. J Clin Oncol 2003;21:1180-9.
16.
Jamieson S, Butzow R, Andersson N, et al. The
FOXL2 C134W mutation is characteristic of
adult granulosa cell tumors of the ovary. Mod
Pathol 2010.
17.
Shah SP, Kobel M, Senz J, et al. Mutation of
FOXL2 in granulosa-cell tumors of the ovary.
N Engl J Med 2009;360:2719-29.
18.
Mom CH, Engelen MJ, Willemse PH, et al.
Granulosa cell tumors of the ovary: the clini-
cal value of serum inhibin A and B levels in
a large single center cohort. Gynecol Oncol
2007;105:365-72.
19.
Long WQ, Ranchin V, Pautier P, et al. Detection
of minimal levels of serum anti-Mullerian hor-
mone during follow-up of patients with ovarian
granulosa cell tumor by means of a highly sen-
sitive enzyme-linked immunosorbent assay. J
Clin Endocrinol Metab 2000;85:540-4.
20.
Rey R, Sabourin JC, Venara M, et al. Anti-
Mullerian hormone is a specific marker of
sertoli- and granulosa-cell origin in gonadal
tumors. Hum Pathol 2000;31:1202-8.
21.
Streuli I, Fraisse T, Pillet C, et al. Serum
antimullerian hormone levels remain stable
throughout the menstrual cycle and after oral
or vaginal administration of synthetic sex ste-
roids. Fertil Steril 2008;90:395-400.
